Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease
Status:
Withdrawn
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy of the addition of infliximab to conventional initial
treatment (intravenous immunoglobulin [IVIG] plus aspirin) in early regression of coronary
artery lesion in patients with Kawasaki disease (KD).
Phase:
Phase 3
Details
Lead Sponsor:
Children's Hospital of Fudan University
Collaborators:
Shanghai 10th People's Hospital Shanghai Children's Hospital Shanghai Children's Medical Center Xinhua Hospital, Shanghai Jiao Tong University School of Medicine